

S5 Table. Parts 1 and 2: adverse events leading to treatment discontinuation by individual patient (n=16)

Dose (mg)	Adverse event(s) leading to treatment discontinuation
81	Fatigue, peripheral edema, dyspnea, pneumonitis
81	Agitation, pulmonary embolism
201	Malignant hypertension
201	Disease progression, cerebral hemorrhage
403	Gastric tumor bleeding
604	Sinusitis
604	Pneumonitis
685	Ascites
685	Cholangitis
685	Fatigue
685	Anal abscess
685	Gastric tumor bleeding
685	Sternal fracture, seizure, acute kidney injury, hemothorax, hemorrhagic shock
685	Increased bilirubin
685	Rectal obstruction
685	Disease progression